Increased risk of chronic kidney disease in elderly with metabolic syndrome and high levels of C-reactive protein: Kahrizak elderly study

Kidney and Blood Pressure Research

Volumn 32, Issue 6, 2010, Pages 457-463

  Fakhrzadeh, Hossein ^a   Ghaderpanahi, Maryam ^a   Sharifi, Farshad ^a,b   Badamchizade, Zohre ^a   Mirarefin, Mojde ^a   Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

Author keywords

C reactive protein; Chronic kidney disease; CKD, elderly population; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IRAN; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 73649092804     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000274046     Document Type: Article

References (32)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003;92:35i-42i.
3. Fakhrzadeh H, Ebrahimpour P, Pourebrahim R, Heshmat R, Larijani B: Metabolic syndrome and its associated risk factors in healthy adults: a population-based study in Iran. Metab Syndr Relat Disord 2006;4:28-34.
4. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140:167-174.
5. Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al: Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant 2007;22:1100-1106.
6. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K: Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69:369-374.
7. Lee JE, Choi SY, Huh W, Kim YG, Kim DJ, Oh HY: Metabolic syndrome, C-reactive protein, and chronic kidney disease in non-diabetic, nonhypertensive adults. Am J Hypertens 2007;20:1189-1194.
8. Wang Q, Chen X, Zhao Y, Gao K, Sun YG, YangM: Association between metabolic syndrome and chronic kidney disease. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:618-622.
9. Zhang L, Zuo L, Wang F, Wang M, Wang S, Liu L, Wang H: Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 2007;82:822-827.
10. Rashidi A, Ghanbarian A, Azizi F: Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screeningpopulation. Clin J Am Soc Nephrol 2007;2:976-983.
11. Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitchaiporn S, Unkurapinun N, Pakpeankitvatana V, et al: The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 2007;71: 693-700.
12. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al: Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006;48:383-291.
13. Kurella M, Lo JC, Chertow G: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
14. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al: Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 2007;30:937-943.
15. Kidney Disease Outcome Quality Initiative: Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1-S246.
16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
17. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745-753.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
19. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
20. Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3A-11A.
21. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:155A.
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
23. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
24. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
25. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59: 260-269.
26. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002;62:1743-1749.
27. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, et al: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9: 1482-1488.
28. Keane WF, O'Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187-194.
29. Nishida Y, Yorioka N, Oda H, Yamakido M: Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 1997;29: 919-930.
30. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397.
31. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
32. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK: Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577-586.